[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Ahmed B, Landuyt W, Griffioen AW, Van Oosterom A, Van den Bogaert W, Lambin P: In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation. Anticancer Res; 2006 Jan-Feb;26(1A):307-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Syngenic rat rhabdomyosarcoma (R1), growing subcutaneously, was treated at 2 different sizes: either small (2 +/- 0.5 cm3) or large (10.94 +/- 0.6 cm3).
  • Localised fractionated irradiation of the tumours (5 x 3 Gy) in 5 days was followed 1 day later by an intraperitoneal CA-4-P treatment (25 mglkg).
  • RESULTS: The combined treatment of only large tumours resulted in a small additional growth delay when compared with radiotherapy only.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy. Stilbenes / pharmacology
  • [MeSH-minor] Animals. Combined Modality Therapy. Dose Fractionation. Male. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475711.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Stilbenes; I5590ES2QZ / fosbretabulin
  •  go-up   go-down


2. Collingridge DR, Rockwell S: Pentoxifylline improves the oxygenation and radiation response of BA1112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas. Int J Cancer; 2000 Oct 20;90(5):256-64
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pentoxifylline improves the oxygenation and radiation response of BA1112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas.
  • Tumor hypoxia can significantly impact the efficacy of cancer therapy.
  • Pentoxifylline, a methylxanthine derivative, can improve oxygen delivery to tissues and is widely used in the treatment of peripheral vascular disease and various cerebrovascular disorders.
  • Our findings confirm that preirradiation administration of pentoxifylline can improve radiation efficacy, but suggest that its role as a postirradiation modifier of treatment response, reported by others, may be tumor-specific.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Mammary Neoplasms, Animal / drug therapy. Mammary Neoplasms, Animal / radiotherapy. Oxygen / metabolism. Pentoxifylline / therapeutic use. Radiation-Protective Agents / therapeutic use. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy
  • [MeSH-minor] Animals. Anoxia. Cell Survival. Combined Modality Therapy. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Pressure. Radiation-Sensitizing Agents / therapeutic use. Rats. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • American Type Culture Collection. culture/stock collections - ATCC CRL-2755 (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11091349.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; 0 / Radiation-Sensitizing Agents; S88TT14065 / Oxygen; SD6QCT3TSU / Pentoxifylline
  •  go-up   go-down


3. Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbeken EK, Ahmed B, Sun X, Ni Y, Bosmans H, Hermans R, van Oosterom A, Marchal G, Landuyt W: Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia; 2005 Aug;7(8):779-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The noninvasive assessment of anticancer treatment efficacy is very important for the improvement of therapeutic window.
  • The purpose of the present study was to evaluate the antitumoral effects of the vascular targeting agent, combretastatin A-4 phosphate (CA-4-P), at selected time points after repeated intraperitoneal drug administrations (25 mg/kg), using diffusion-weighted magnetic resonance imaging (DW-MRI).
  • The changes in ADC as well as the extent of necrosis development (proportional to the tumor volume), measured on the MR images, were of comparable magnitude after each treatment.
  • Repeated CA-4-P administration retains efficacy in rat rhabdomyosarcomas, with similar findings after each drug administration.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Diffusion Magnetic Resonance Imaging. Rhabdomyosarcoma / drug therapy. Stilbenes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 2000 Jun;43(6):828-36 [10861877.001]
  • [Cites] Radiology. 2005 Mar;234(3):756-64 [15734932.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36 [11121466.001]
  • [Cites] NMR Biomed. 2002 Feb;15(1):6-17 [11840548.001]
  • [Cites] NMR Biomed. 2002 Apr;15(2):89-98 [11870904.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2060-9 [11877280.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):255-62 [11988845.001]
  • [Cites] Int J Exp Pathol. 2002 Feb;83(1):21-38 [12059907.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3408-16 [12067983.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):307-8 [12147376.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):717-26 [12239609.001]
  • [Cites] Int J Cancer. 2002 Nov 1;102(1):70-4 [12353236.001]
  • [Cites] Radiology. 2003 Jan;226(1):71-8 [12511671.001]
  • [Cites] Eur J Radiol. 2003 Mar;45(3):208-13 [12595105.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1144-7 [12615734.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1094-100 [12637476.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):20-5 [12672025.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):958-65 [12829130.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2815-22 [12807934.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2823-30 [12807935.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2831-42 [12807936.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):336-43 [12926229.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4428-38 [14645433.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):415-27 [14760060.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):150-7 [15140404.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2491-9 [15197790.001]
  • [Cites] Cancer Metastasis Rev. 1990 Nov;9(3):267-82 [2292139.001]
  • [Cites] Semin Cancer Biol. 1992 Apr;3(2):89-96 [1378314.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):591-9 [1503032.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):61-4 [8554985.001]
  • [Cites] Radiology. 1998 Jan;206(1):227-35 [9423677.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1761-7 [9667644.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1626-34 [10197639.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1A):189-95 [10226542.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1833-43 [10974632.001]
  • (PMID = 16207480.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Stilbenes; I5590ES2QZ / fosbretabulin
  • [Other-IDs] NLM/ PMC1501887
  •  go-up   go-down


Advertisement
4. Gottschalk A, Raabe A, Hommel M, Rempf C, Freitag M, Standl T: Influence of the hemoglobin solution HBOC-201 on tissue oxygenation in the rat R1H-tumor. Artif Cells Blood Substit Immobil Biotechnol; 2005;33(4):379-89
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the hemoglobin solution HBOC-201 on tissue oxygenation in the rat R1H-tumor.
  • It has already been used in clinical phase II/III trials for emergency treatments.
  • Animal experiments have shown that HBOC-201 is highly effective in tissue oxygenation.
  • METHODS: 30 rats with a subcutaneously growing rhabdomyosarcoma R1H tumor were randomly assigned either to be ventilated with carbogen (n = 10), or to receive an IV injection of 0.3 g/kg HBOC-201 (n = 10) or a combination of 0.3 g/kg HBOC-201 and carbogen breathing (n = 10).
  • Under general anesthesia the effects of the respective treatment on the tissue oxygen tension (tpO2) of the tumor were determined using a flexible stationary probe at baseline (b) and 15 and 60 min after application of the respective medication.
  • CONCLUSION: The application of low dose hemoglobin solution HBOC-201 does not result in improvement of tissue oxygenation in the rat rhabdomyosarcoma R1H.
  • [MeSH-major] Hemoglobins / pharmacology. Oxygen / metabolism. Rhabdomyosarcoma / metabolism
  • [MeSH-minor] Animals. Anoxia / drug therapy. Blood Substitutes / administration & dosage. Blood Substitutes / pharmacology. Carbon Dioxide / administration & dosage. Carbon Dioxide / pharmacology. Drug Evaluation, Preclinical. Rats. Tissue Distribution / drug effects

  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317957.001).
  • [ISSN] 1073-1199
  • [Journal-full-title] Artificial cells, blood substitutes, and immobilization biotechnology
  • [ISO-abbreviation] Artif Cells Blood Substit Immobil Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Substitutes; 0 / HBOC 201; 0 / Hemoglobins; 142M471B3J / Carbon Dioxide; 8063-77-2 / carbogen; S88TT14065 / Oxygen
  •  go-up   go-down


5. van den Berg AP, van den Berg-Blok AE, Kal HB, Reinhold HS: A moderate elevation of blood glucose level increases the effectiveness of thermoradiotherapy in a rat tumor model II. Improved tumor control at clinically achievable temperatures. Int J Radiat Oncol Biol Phys; 2001 Jul 1;50(3):793-801
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A moderate elevation of blood glucose level increases the effectiveness of thermoradiotherapy in a rat tumor model II. Improved tumor control at clinically achievable temperatures.
  • PURPOSE: To assess the therapeutic gain (at the TCD(50) level) that can be obtained by boosting thermoradiotherapy with intravenous glucose infusion at different temperatures.
  • This completes our series of studies to determine the optimal conditions and the effectiveness of glucose administration at clinically achievable glucose levels and treatment temperatures.
  • METHODS AND MATERIALS: Subcutaneous rat rhabdomyosarcoma BA1112 was irradiated with graded single doses of 300-kV X-rays (dose range 0-60 Gy).
  • Tumor control was scored as the absence of palpable growth at 100 days after treatment.
  • At 42 degrees C, the TCD(50) for X-irradiation decreased by 5.9 Gy (SEM 1.8 Gy), from 41.6 (1.6) to 35.7 (1.5) Gy, and at 43 degrees C from 33.3 (1.6) to 27.3 (1.5) Gy, representing a glucose enhancement ratio of approximately 1.2.
  • An enhancement ratio of 2.1 was found for the combination of irradiation, glucose infusion, and heating at 43 degrees C, with respect to irradiation alone (TCD(50) 56.3 Gy, reanalyzed earlier data).
  • Clinical treatment should benefit from this additional modality, in particular if unsatisfactory local control rates are due to insufficient heating.
  • The therapeutic gain has to be evaluated further in clinical studies.
  • [MeSH-major] Blood Glucose / metabolism. Glucose / pharmacology. Hyperthermia, Induced. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Hydrogen-Ion Concentration. Infusions, Intravenous. Logistic Models. Rats

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11395249.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; IY9XDZ35W2 / Glucose
  •  go-up   go-down


6. Raabe A, Buchert R, Seegers B, de Wit M: Potential time benefit in the assessment of recurrent rat rhabdomyosarcoma using positron emission tomography (PET) with (18)fluorodeoxyglucose depends on therapy-specific growth delay. Strahlenther Onkol; 2006 Oct;182(10):610-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential time benefit in the assessment of recurrent rat rhabdomyosarcoma using positron emission tomography (PET) with (18)fluorodeoxyglucose depends on therapy-specific growth delay.
  • PURPOSE: To correlate the potential time benefit of (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) in terms of early detection of recurrences of subcutaneously growing R1H tumors with therapy-specific parameters of recurrent tumor.
  • MATERIAL AND METHODS: Twelve, eleven, and seven recurrences were followed after fractionated radiotherapy, surgery, and chemotherapy for 6 months, respectively, and (18)FDG-PET was performed weekly using a conventional full-ring whole-body PET scanner.
  • By comparing PET results and actual tumor volume, the time benefit of (18)FDG-PET in detection of recurrent tumors of 0.1, 0.2, and 0.5 cm(3) was determined for the different treatment strategies.
  • RESULTS: A significant time benefit of (18)FDG-PET of 26.9 days and 67 days was solely determined for recurrences after radiotherapy of 0.2 cm(3) and 0.5 cm(3), respectively.
  • The potential time benefit showed a strong correlation with growth delay, which was increased after radiotherapy due to a pronounced tumor-bed effect.
  • CONCLUSION: The potential time benefit of (18)FDG-PET is strongly determined by the growth kinetics of the recurrence.
  • A tumor-bed effect, which is a phenomenon solely seen after radiotherapy, favors early detection by (18)FDG-PET.
  • The experimental data, clinical experience and theoretical consideration all indicate a noticeable benefit of (18)FDG-PET especially after radiotherapeutic treatment.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Recurrence, Local / radiotherapy. Positron-Emission Tomography / methods. Rhabdomyosarcoma / radionuclide imaging. Rhabdomyosarcoma / radiotherapy
  • [MeSH-minor] Animals. Feasibility Studies. Radiopharmaceuticals. Rats. Reproducibility of Results. Sensitivity and Specificity. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013575.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


7. Landuyt W, Theys J, Nuyts S, Drijkoningen M, Fowler J, Reijnders A, Liekens S, Neyts J, de Bruijn E, Anné J, Lambin P: Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors of different sizes. Cancer Invest; 2001;19(1):35-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors of different sizes.
  • Potential anticancer therapy with the fumagillin analog TNP-470 was investigated in the present project using subcutaneously growing rhabdomyosarcomas in rats.
  • Specifically, influences of different tumor sizes at the start of treatment as well as dose/schedules were evaluated with this angiogenesis inhibitor.
  • Overall, both tumor volume and drug dose determine treatment outcome with the rat rhabdomyosarcoma.
  • The results suggest that angiogenesis inhibitors could represent a valid component in the treatment of progressive tumor growth, also of large tumors as often encountered in clinics.
  • The antivasculature therapy might also improve hypoxia/necrosis-related therapeutic approaches.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Rhabdomyosarcoma / drug therapy. Sesquiterpenes / therapeutic use
  • [MeSH-minor] Animals. Cell Survival. Cyclohexanes. Drug Administration Schedule. Male. Necrosis. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291554.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cyclohexanes; 0 / Sesquiterpenes; 129298-91-5 / O-(chloroacetylcarbamoyl)fumagillol
  •  go-up   go-down


8. Morita K, Zywietz F, Kakinuma K, Tanaka R, Katoh M: Efficacy of doxorubicin thermosensitive liposomes (40 degrees C) and local hyperthermia on rat rhabdomyosarcoma. Oncol Rep; 2008 Aug;20(2):365-72
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of doxorubicin thermosensitive liposomes (40 degrees C) and local hyperthermia on rat rhabdomyosarcoma.
  • The efficacy of novel thermosensitive liposomes (40 degrees C) containing doxorubicin (Dox-Lip) together with local hyperthermia (HT) was studied on solid growing rat rhabdomyosarcomas.
  • Tumors were heated with infrared-A-radiation and drugs were infused intravenously after preheating the tumors followed by a further 60 min of heating at 42.5 degrees C.
  • Repeated treatments with Dox-Lip+HT (2x2.5 mg/kg+HT/2 weeks) resulted in a statistically significant tumor growth delay and was associated with a much lower systemic toxicity.
  • Uptake studies of drugs in blood, tumor and normal tissues showed that Dox-liposomes (40 degrees C) are long circulating liposomes in the blood.
  • The findings suggest that repeated applications of thermosensitive liposomal doxorubicin (40 degrees C) and local hyperthermia can control primary rat rhabdomyosarcomas while reducing the systemic toxicity of free doxorubicin.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / therapeutic use. Hyperthermia, Induced. Rhabdomyosarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Animals. Body Weight / drug effects. Combined Modality Therapy. Disease Models, Animal. Drug Carriers. Liposomes. Male. Rats. Rats, Inbred Strains. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636199.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Carriers; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


9. Kehrl W, Sagowski C, Wenzel S, Zywietz F: Oxygenation of tumor recurrences following fractionated radiotherapy of primary tumors. Studies on the rhabdomyosarcoma R1H of the rat. Strahlenther Onkol; 2004 Jun;180(6):383-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxygenation of tumor recurrences following fractionated radiotherapy of primary tumors. Studies on the rhabdomyosarcoma R1H of the rat.
  • MATERIAL AND METHODS: Tumor oxygenation in primary tumors and recurrences of rat rhabdomyosarcomas R1H was measured by using pO(2) probes and Eppendorf pO(2) histography.
  • Primary tumors were irradiated at a (60)Co radiotherapy facility with a total dose of 75 Gy, given in 30 fractions over 6 weeks.
  • The histological sections of the R1H recurrences showed a higher heterogeneity in their tissue structure than primary nonirradiated tumors.
  • CONCLUSION: In R1H rhabdomyosarcomas tumor oxygenation in recurrent tumors following radiation therapy is significantly lower than in primary tumors.
  • This observation has to be taken into account in cases of tumor recurrences where repeated radiotherapy, chemotherapy or combined treatment modalities are used.
  • [MeSH-major] Oxygen Consumption / radiation effects. Rhabdomyosarcoma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15175874.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


10. Castro B, Alonso-Varona A, del Olmo M, Bilbao P, Palomares T: Role of gamma-glutamyltranspeptidase on the response of poorly and moderately differentiated rhabdomyosarcoma cell lines to buthionine sulfoximine-induced inhibition of glutathione synthesis. Anticancer Drugs; 2002 Mar;13(3):281-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of gamma-glutamyltranspeptidase on the response of poorly and moderately differentiated rhabdomyosarcoma cell lines to buthionine sulfoximine-induced inhibition of glutathione synthesis.
  • The aim of the present work is to study the effect of buthionine sulfoximine (BSO, a specific cellular GSH-depleting agent) in two rat tumor cell lines derived from the same rhabdomyosarcoma tumor model, the moderately differentiated and low metastatic F21 cell line, and the poorly differentiated and high metastatic S4MH cell line, to investigate the influence of the degree of differentiation in the induction of GSH depletion-based therapy.
  • These effects were in consonance with the fact that the activity of gamma-glutamyltranspeptidase (gamma-GT) present in the F21 cells was 4 times higher than in the S4MH cells.
  • These studies suggest that, as occurs in the rhabdomyosarcoma tumor model, gamma-GT levels and the degree of differentiation of tumor cells might influence the response of tumor cells to inducers of GSH depletion, and should be taken into account in therapies based on GSH metabolism.
  • [MeSH-major] Buthionine Sulfoximine / pharmacology. Enzyme Inhibitors / pharmacology. Glutathione / metabolism. Rhabdomyosarcoma / pathology. gamma-Glutamyltransferase / antagonists & inhibitors
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Differentiation / drug effects. Cell Division / drug effects. Cell Line. Dose-Response Relationship, Drug. Female. Humans. Isoxazoles / pharmacology. Rats. Rats, Wistar. Tumor Cells, Cultured / enzymology. Tumor Cells, Cultured / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11984072.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Isoxazoles; 5072-26-4 / Buthionine Sulfoximine; EC 2.3.2.2 / gamma-Glutamyltransferase; GAN16C9B8O / Glutathione; O0X60K76I6 / acivicin
  •  go-up   go-down


11. Palomares T, Castro B, del Olmo M, Iglesias A, Bilbao P, Alonso-Varona A: Influence of the level of gamma-glutamyltranspeptidase activity on the response of poorly and moderately differentiated rhabdomyosarcoma cell lines to all-trans-retinoic acid. Anticancer Drugs; 2006 Nov;17(10):1127-39
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the level of gamma-glutamyltranspeptidase activity on the response of poorly and moderately differentiated rhabdomyosarcoma cell lines to all-trans-retinoic acid.
  • Differentiation therapy with retinoic acid has been considered a potential approach for treating rhabdomyosarcoma.
  • Analysis of retinoids as differentiating agents for rhabdomyosarcoma is, however, rendered incomplete by the fact that some rhabdomyosarcoma cell lines are retinoic acid resistant.
  • Therefore, the aim of the present work was to study the effect of all-trans-retinoic acid on two rat tumour cell lines, derived from the same rhabdomyosarcoma tumour model (i.e. the moderately differentiated low metastatic F21 cell line and the poorly differentiated high metastatic S4MH cell line), to discover how degree of differentiation and glutathione metabolism influence response to this retinoic acid derivative.
  • The pro-tumour effect observed in F21 cells was reversed by adding buthionine sulphoximide, a specific cellular glutathione-depleting agent, to the all-trans-retinoic acid treatment.
  • Our findings suggest that the response to all-trans-retinoic-acid of the tumour cell lines studied is influenced by the strong relationship between intracellular glutathione content, gamma-glutamyltranspeptidase activity and degree of differentiation of the rhabdomyosarcoma cell line, and that this relationship should be taken into account when identifying 'retinoid-sensitive' tumours.
  • [MeSH-major] Rhabdomyosarcoma / metabolism. Rhabdomyosarcoma / pathology. Tretinoin / pharmacology. gamma-Glutamyltransferase / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Buthionine Sulfoximine / pharmacology. Cell Differentiation / drug effects. Cell Proliferation / drug effects. Drug Combinations. Female. Glutathione / analysis. Rats. Rats, Wistar. Reactive Oxygen Species / analysis. Transplantation, Homologous / pathology. Tumor Burden / drug effects. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075312.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Reactive Oxygen Species; 5072-26-4 / Buthionine Sulfoximine; 5688UTC01R / Tretinoin; EC 2.3.2.2 / gamma-Glutamyltransferase; GAN16C9B8O / Glutathione
  •  go-up   go-down


12. Zywietz F, Böhm L, Sagowski C, Kehrl W: Pentoxifylline enhances tumor oxygenation and radiosensitivity in rat rhabdomyosarcomas during continuous hyperfractionated irradiation. Strahlenther Onkol; 2004 May;180(5):306-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pentoxifylline enhances tumor oxygenation and radiosensitivity in rat rhabdomyosarcomas during continuous hyperfractionated irradiation.
  • MATERIAL AND METHODS: Tumor oxygenation in rat rhabdomyosarcomas R1H after PTX administration (50 mg/kg body weight) was measured using interstitial pO(2) probes (Licox CMP system and Eppendorf pO(2)-Histograph).
  • Tumors were irradiated with (60)Co gamma-irradiation using single doses (15 and 30 Gy), conventional fractionation (60 Gy/30 fractions/6 weeks), and continuous hyperfractionation (54 Gy/36 fractions/18 days) in combination with PTX or an equivalent volume of physiological saline.
  • RESULTS: PTX increased tumor oxygenation for up to 45 min after administration of the drug.
  • Single doses of 15 and 30 Gy of irradiation, when combined with PTX, produced little radiosensitization of the R1H tumors as indicated by dose-modifying factors (DMFs) of 1.11 and 1.04, respectively.
  • [MeSH-major] Oxygen / metabolism. Pentoxifylline / administration & dosage. Radiation Tolerance / drug effects. Rhabdomyosarcoma / metabolism. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Animals. Cell Survival / drug effects. Cell Survival / radiation effects. Combined Modality Therapy / methods. Dose Fractionation. Dose-Response Relationship, Radiation. Male. Platelet Aggregation Inhibitors / administration & dosage. Radiotherapy Dosage. Rats. Treatment Outcome

  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15127161.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; S88TT14065 / Oxygen; SD6QCT3TSU / Pentoxifylline
  •  go-up   go-down


13. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, Stockx L, Wynendaele W, Fowler JF, Maleux G, Van den Bogaert W, Anné J, van Oosterom A, Lambin P: Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer; 2000 Sep;36(14):1833-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas.
  • Tumour-specific vascularisation may be therapeutically approached in two different ways: by antiangiogenic treatments specifically directed to dividing and migrating endothelial cells, or by agents that target principally the inadequate and ill-structured tumour vasculature.
  • Different tumour volume groups, ranging between 0.1 and 27 cm(3), were selected to assess the relationship between the size at treatment time and the response to combreAp.
  • A double combreAp treatment (2x25 mg/kg) was investigated within the same overall aim: the relationship between growth delay and tumour size.
  • Our results show that the systemic administration of combreAp induces a clear-cut differential growth delay in the solid rat rhabdomyosarcomas: with very large tumours (>/= 14 cm(3)), a 17.6-fold stronger effect was measured than with very small tumours (<1 cm(3)).
  • This is the 'inverse' of the volume-response seen with the conventional therapeutic approaches (radiotherapy, chemotherapy or surgery).
  • These combreAp antitumour responses were observed without treatment limiting systemic toxicity in the rats.
  • This significant differential volume-response obtained with 'selective' vascular targeting, stronger in larger tumours than smaller ones, suggests the potential of broadening the therapeutic window.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Neovascularization, Pathologic / drug therapy. Rhabdomyosarcoma / drug therapy. Stilbenes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974632.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Stilbenes; I5590ES2QZ / fosbretabulin
  •  go-up   go-down


14. van den Berg AP, van den Berg-Blok AE, Kal HB, Reinhold HS: A moderate elevation of blood glucose level increases the effectiveness of thermoradiotherapy in a rat tumor model. I. Relative contributions of glucose and heating to tumor acidification. Int J Radiat Oncol Biol Phys; 2001 Jul 1;50(3):783-92
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A moderate elevation of blood glucose level increases the effectiveness of thermoradiotherapy in a rat tumor model. I. Relative contributions of glucose and heating to tumor acidification.
  • PURPOSE: To establish dose-effect relationships for tumor acidification induced by heat and glucose as a basis for testing the value of adding glucose administration to combined heat and x-ray treatment at clinically achievable glucose and temperature levels.
  • METHODS AND MATERIALS: Rhabdomyosarcoma BA1112 was grown s.c. in the upper leg of 16-20-week-old Wag/Rij rats.
  • Its predicted superiority in thermoradiotherapy as compared with S37S42, S37S43, and G37G42 treatment regimens was confirmed in a subsequent experimental tumor control study.
  • [MeSH-major] Blood Glucose / metabolism. Glucose / pharmacology. Hyperthermia, Induced. Rhabdomyosarcoma / metabolism. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Hydrogen-Ion Concentration. Rats

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11395248.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; IY9XDZ35W2 / Glucose
  •  go-up   go-down


15. Lambin P, Landuyt W: Vascular targeting: a potential additional anti-cancer treatment. Verh K Acad Geneeskd Belg; 2003;65(1):29-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular targeting: a potential additional anti-cancer treatment.
  • Using a clinical angiography method and the tumour growth delay assay, the efficacy of the vascular targeting compound combretastatin A-4 phosphate was demonstrated in rat rhabdomyosarcomas: specifically, an inverse efficacy as compared to radio- or chemotherapy was measured when comparing small and large tumours.
  • Within the limits of our experiments, no significant increase in tumour growth delay was measured when TNP-470 anti-angiogenesis was given after the combretastatin A-4 phosphate treatment.
  • The use of the vascular targeting agent did advance the in vivo application of a non-apathogenic anaerobe Clostridium transfer system of therapeutic proteins.
  • In summary, the present preclinical results demonstrate several advantages from the introduction of vascular targeting next to classical and novel anti-cancer therapies.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Neovascularization, Pathologic / drug therapy. Rhabdomyosarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Stilbenes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12802895.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Stilbenes; I5590ES2QZ / fosbretabulin
  • [Number-of-references] 41
  •  go-up   go-down


16. Dörr W: Effects of selenium on radiation responses of tumor cells and tissue. Strahlenther Onkol; 2006 Dec;182(12):693-5
Hazardous Substances Data Bank. SELENIUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of selenium on radiation responses of tumor cells and tissue.
  • PURPOSE: This review summarizes information about modulation of radiation effects in tumor cells and tissues by selenium.
  • In experimental animal tumors, a positive effect of selenium was observed with chemotherapy.
  • None of the investigations demonstrated a negative effect on the tumor response to therapy.
  • CONCLUSION: The only study with fractionated irradiation was performed in a rat R1H tumor, which does not show accelerated repopulation.
  • For local administration of normal tissues with selenium, potential tumor effects may be of less importance, but these may be relevant for systemic administration.
  • [MeSH-major] Cell Survival / radiation effects. Dose Fractionation. Radiation Injuries, Experimental / prevention & control. Radiation Tolerance / drug effects. Radiation-Protective Agents / pharmacology. Selenium Compounds / pharmacology. Tumor Cells, Cultured / radiation effects. Tumor Stem Cell Assay
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / radiation effects. Combined Modality Therapy. Dose-Response Relationship, Radiation. Humans. Mice. Neoplasm Transplantation. Rats. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Strahlenther Onkol. 2007 Jun;183(6):344-5 [17520190.001]
  • (PMID = 17149574.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; 0 / Selenium Compounds
  • [Number-of-references] 31
  •  go-up   go-down


17. Vergani L, Malena A, Sabatelli P, Loro E, Cavallini L, Magalhaes P, Valente L, Bragantini F, Carrara F, Leger B, Poulton J, Russell AP, Holt IJ: Cultured muscle cells display defects of mitochondrial myopathy ameliorated by anti-oxidants. Brain; 2007 Oct;130(Pt 10):2715-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the muscle-specific pathophysiology of mitochondrial disease, rhabdomyosarcoma transmitochondrial hybrid cells (cybrids) were generated that retain the capacity to differentiate to myotubes.
  • In some cases, striated muscle-like fibres were formed after innervation with rat embryonic spinal cord.
  • All these features were ameliorated by anti-oxidant treatment, with the exception of the paracrystalline inclusions.
  • These data suggest that rhabdomyosarcoma cybrids are a valid cellular model for studying muscle-specific features of mitochondrial disease and that excess reactive oxygen species production is a significant contributor to mitochondrial dysfunction, which is amenable to anti-oxidant therapy.
  • [MeSH-minor] Adult. Animals. Cell Differentiation. Cells, Cultured. DNA, Mitochondrial / genetics. Gene Expression Regulation. Humans. Male. Microscopy, Electron. Mitochondria, Muscle / drug effects. Mitochondria, Muscle / ultrastructure. Muscle Fibers, Skeletal / metabolism. Oxidation-Reduction. Rats. Rats, Sprague-Dawley. Reactive Oxygen Species / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mitochondrial myopathy.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626036.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Grant] Italy / Telethon / / 1252; United Kingdom / Medical Research Council / / G0500695; United Kingdom / Medical Research Council / / MC/ U105663140
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA, Mitochondrial; 0 / Reactive Oxygen Species
  •  go-up   go-down


18. Growcott JW: Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs; 2009 Feb;20(2):83-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endothelins are a family of small peptides (ET-1, ET-2, and ET-3) that mediate various physiological processes of mitogenesis, repair, and tissue differentiation by binding to endothelin A (ETA) and endothelin B (ETB) cell surface receptors.
  • Activation of the ETA receptor by ET-1 has emerged as an important factor promoting tumor cell proliferation, survival, angiogenesis, migration, invasion, and metastasis in several tumor types including prostate, ovary, colon, cervix, breast, and lung.
  • As activation of the ETB receptor has an opposing effect, inducing cell death by apoptosis, a rationale exists for specific antagonism of the ETA receptor as a treatment strategy for cancer.
  • In vitro, ZD4054 reversed ET-1-mediated inhibition of apoptosis in serum-deprived rat A10 and human VLTR-16 cells in a concentration-dependent manner.
  • In A673 rhabdomyosarcoma cells, ET-1-induced phosphorylation of FAK, FAK, and paxillin was reversed with ZD4054, inhibiting the invasive phenotype mediated by these adhesion factors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endothelin A Receptor Antagonists. Neoplasms / drug therapy. Pyrrolidines / therapeutic use
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Proliferation / drug effects. Drug Evaluation, Preclinical. Humans. Neovascularization, Pathologic / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065106.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endothelin A Receptor Antagonists; 0 / Pyrrolidines; 0 / ZD4054
  • [Number-of-references] 35
  •  go-up   go-down






Advertisement